Top Ten most popular articles on Pharmafile.com this week
pharmafile | February 7, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | MERS, Sars, china coronavirus, coronavirus, coronavirus China, wuhan coronaviurs
The Wuhan coronavirus continues to dominate the news, with China admitting its handling of the crisis had shortcomings while Gilead has been testing its experimental Ebola drug on patients with the coronavirus. A baby born in February has also been diagnosed with the disease but doctors are still unclear if its infected mother transferred it during or after preganancy.
In other news, the FDA has approved its first treatment for peanut allergy in patients between ages four and 17, while Sanofi has been charged with failure to adequately warn patients about their anti-epilepsy drug which has been linked to birth defects.
10. NICE plans to use broader range of data in guidance
The British National Institute for Care Excellence has said it plans to use a broader range of data and analytics in its guidance. This will include real-world evidence and electronic health records.
9. Bayer’s Eylea shows strong vision benefits across two regimens in post-marketing study
Bayer has pulled back the curtain on new Phase 4 data for Eylea (aflibercept), revealing strong findings in the treatment of wet age-related macular degeneration (AMD) via two different Treat and Extend (T&E) dosing regimens.
8. Europe’s CHMP recommends Pfizer’s biosimilar of Roche’s MabThera
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has revealed that it has awarded a positive opinion for Pfizer’s Ruxience, a biosimilar version of Roche’s MabThera (rituximab).
7. Gilead’s experimental Ebola drug being tested in patients infected with coronavirus
China and the US are testing Gilead’s remdesivir in patients with the coronavirus, in the hopes of developing an effective treatment for a disease that does not yet have a vaccine.
6. Healthy cells in lungs can repair the damage from smoking
Human lungs have the ‘magical’ ability to repair the cancerous mutations caused by smoking cigarettes, but only if people quit smoking.
5. Sanofi charged in birth defects case in France
Sanofi has been charged with failure to adequately warn patients about their anti-epilepsy drug which has been linked to birth defects.
4. China admits its coronavirus response had “shortcomings”
In a rare move, China’s leadership has admitted “shortcomings” in the way it has handled the outbreak of the deadly coronavirus.
3. FDA approves first treatment for peanut allergy
The FDA has approved its first treatment for peanut allergy in patients between ages four and 17.
2. BMS pulls Opdivo+Yervoy combo in EU for advanced non-small cell lung cancer
Bristol-Myers Squibb has confirmed it has withdrawn its application with the European Commission for its combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of advanced non-small cell lung cancer (NSCLC).
1. Newborn baby diagnosed with coronavirus
A baby born this month in Wuhan China has been diagnosed with the coronavirus.
Related Content
EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention
AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application …
Pharmafile.com’s weekly COVID-19 news round-up
The past week has continued to see positive COVID-19 news; CytoDyn’s treatment for patients with …
GSK’s Phase II otilimab study on COVID-19 patients promising for over-70s
GlaxoSmithKline’s (GSK) Phase II OSCAR study of their otilimab antibody’s effect on COVID-19 patients has …
